News | September 14, 2023
Zydus receives EIR for injectables manufacturing facility at Zydus Biotech Park, Ahmedabad
The inspection was a cGMP Inspection and had ended with NIL observations
The inspection was a cGMP Inspection and had ended with NIL observations
The inspection classification was determined by the agency as Voluntary Action Indicated
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events
Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
Eris Lifesciences enters into term loan agreement with Citi Bank
Oteseconazole Capsules were found to be safe and more effective than fluconazole
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Subscribe To Our Newsletter & Stay Updated
